T1	p 92 114	stable COPD patients .
T2	p 129 144	COPD patients ,
T3	p 596 630	60 COPD patients underwent dyspnea
T4	p 789 800	?sRAW-based
T5	p 842 844	45
T6	p 1250 1287	patients were stratified according to
T7	p 1424 1432	criteria
T8	i 276 277	)
T9	i 718 746	placebo or 300?g indacaterol
T10	i 931 938	?ITGV )
T11	i 982 987	?RV )
T12	i 1013 1017	?FVC
T13	i 1045 1049	?VAS
T14	i 1108 1112	?FVC
T15	i 1172 1179	?ITGV (
T16	i 1192 1195	?RV
T17	i 1352 1367	bronchodilators
T18	o 63 88	airway resistance changes
T19	o 202 229	forced expiratory volume at
T20	o 247 275	forced vital capacity ( ?FVC
T21	o 303 328	airway smooth muscle tone
T22	o 363 400	dynamic hyperinflation , gas trapping
T23	o 407 423	possibly dyspnea
T24	o 462 498	specific airway resistance changes (
T25	o 631 686	evaluation ( VAS score ) and pulmonary function testing
T26	o 904 936	intrathoracic gas volume ( ?ITGV
T27	o 964 985	residual volume ( ?RV
T28	o 1013 1017	?FVC
T29	o 1045 1049	?VAS
T30	o 1192 1195	?RV
T31	o 1214 1218	?VAS
T32	o 1331 1341	functional
T33	o 1488 1530	improvements of lung mechanics and dyspnea